|
1
|
Wald O, Shapira OM and Izhar U:
CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic
roles and therapeutic potential. Theranostics. 3:26–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim SH, Choe C, Shin YS, Jeon MJ, Choi SJ,
Lee J, Bae GY, Cha HJ and Kim J: Human lung cancer-associated
fibroblasts enhance motility of non-small cell lung cancer cells in
co-culture. Anticancer Res. 33:2001–2009. 2013.PubMed/NCBI
|
|
4
|
Franco OE, Shaw AK, Strand DW and Hayward
SW: Cancer associated fibroblasts in cancer pathogenesis. Semin
Cell Dev Biol. 21:33–39. 2010. View Article : Google Scholar :
|
|
5
|
Karagiannis GS, Poutahidis T, Erdman SE,
Kirsch R, Riddell RH and Diamandis EP: Cancer-associated
fibroblasts drive the progression of metastasis through both
paracrine and mechanical pressure on cancer tissue. Mol Cancer Res.
10:1403–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chatterjee S, Behnam Azad B and Nimmagadda
S: The intricate role of CXCR4 in cancer. Adv Cancer Res.
124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y, Jacamo R, Konopleva M, Garzon R,
Croce C and Andreeff M: CXCR4 downregulation of let-7a drives
chemoresistance in acute myeloid leukemia. J Clin Invest.
123:2395–2407. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Perona R and Sánchez-Pérez I: Control of
oncogenesis and cancer therapy resistance. Br J Cancer. 90:573–577.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Han C, Yu Z, Duan Z and Kan Q: Role of
microRNA-1 in human cancer and its therapeutic potentials. Biomed
Res Int. 2014:4283712014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aprelikova O and Green JE: MicroRNA
regulation in cancer-associated fibroblasts. Cancer Immunol
Immunother. 61:231–237. 2012. View Article : Google Scholar
|
|
12
|
Li J, Dong X, Wang Z and Wu J: MicroRNA-1
in cardiac diseases and cancers. Korean J Physiol Pharmacol.
18:359–363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leone V, D'Angelo D, Rubio I, de Freitas
PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco
A: MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting
CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab.
96:E1388–E1398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Solingen C, de Boer HC, Bijkerk R,
Monge M, van Oeveren-Rietdijk AM, Seghers L, de Vries MR, van der
Veer EP, Quax PH, Rabelink TJ, et al: MicroRNA-126 modulates
endothelial SDF-1 expression and mobilization of
Sca-1+/Lin− progenitor cells in ischaemia.
Cardiovasc Res. 92:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang L, Xu AM, Liu S, Liu W and Li TJ:
Cancer-associated fibroblasts in digestive tumors. World J
Gastroenterol. 20:17804–17818. 2014.PubMed/NCBI
|
|
16
|
Du H, Chen D, Zhou Y, Han Z and Che G:
Fibroblast phenotypes in different lung diseases. J Cardiothorac
Surg. 9:1472014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Otsuka S, Klimowicz AC, Kopciuk K,
Petrillo SK, Konno M, Hao D, Muzik H, Stolte E, Boland W, Morris D,
et al: CXCR4 overexpression is associated with poor outcome in
females diagnosed with stage IV non-small cell lung cancer. J
Thorac Oncol. 6:1169–1178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanoun N, Delpu Y, Suriawinata AA, Bournet
B, Bureau C, Selves J, Tsongalis GJ, Dufresne M, Buscail L,
Cordelier P, et al: The silencing of microRNA 148a production by
DNA hypermethylation is an early event in pancreatic
carcinogenesis. Clin Chem. 56:1107–1118. 2010. View Article : Google Scholar : PubMed/NCBI
|
